Vision loss in India
The loss of vision is very debilitating and we have heard startling statistics from our collaborators at the Aravind Eye Care System in South India reporting that 200 million people need eye care in India and less than 10% are treated; 12 million are blind and 80% of these are treatable. The Aravind Eye Care System's vision is to eliminate needless blindness by providing high quality, high volume and compassionate eye care for all.
At the University of Liverpool, we are working with the Aravind Eye Care System through an EPSRC-funded Translational Alliance Platform grant to develop a novel treatment for keratoconus.
Keratoconus is a progressive condition, often affecting young and working age people, in which the cornea becomes misshapen significantly disrupting the refraction of light into the eye. One of the key features of keratoconus is a loss of corneal mechanical stability. Increasing the stiffness of the cornea can reduce the progression of this debilitating eye disease. Corneal collagen cross-linking focuses on stiffening the cornea in order to preserve corneal integrity due to strong bonds formed within the collagen. Using our understanding of the engineering principles that define the relationship between the structure and mechanical properties of materials we are working to develop a novel collagen cross-linking therapy.
Current treatment requires the application of a light sensitive solution to the eye followed by activation with UV light. This means the patient needs to attend a specialist centre for treatment and only patients with thicker cornea can be treated owing to toxicity of the UV light to sensitive cells at the back of the cornea. For the treatment to be really effective it also requires the removal of the outer layer of the cornea which leaves the patient with a very sore eye for several days.
Our new treatment does not require activation with UV light and we believe it could be administered by a simple eye drop which could be done in the community. Our data have demonstrated a lack of toxicity to corneal cells and, most importantly, it is effective without scraping off the corneal surface.
The value of collaboration
During the partnership there have been multiple visits between the Institutions in both directions. In addition one of their research scientists has spent two months in our labs in Liverpool and one of our Postdocs has spent two months in Madurai. The strength of the partnership that we have built is leading to other exciting collaborative projects.
Aurolab is a component part of the Aravind Eye Care System and is a non-profit organisation with a strong R&D ethos based on innovative product development to address societal needs and provide affordable healthcare worldwide. By working with them we aim to produce a high quality product that can deliver treatment directly to patients within the community.
We were very pleased to be invited to present our work on this at the ARVO-ASIA Translational Vision Summit in Brisbane in February 2017.